Raymond James Reiterates “Outperform” Rating for Avantor (NYSE:AVTR)

Avantor (NYSE:AVTR)‘s stock had its “outperform” rating reissued by stock analysts at Raymond James in a research note issued on Monday,Benzinga reports. They presently have a $24.00 target price on the stock, down from their prior target price of $26.00. Raymond James’ target price suggests a potential upside of 27.90% from the stock’s previous close.

Several other research firms have also issued reports on AVTR. UBS Group reaffirmed a “neutral” rating and issued a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Barclays dropped their price objective on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Monday. Royal Bank of Canada reduced their price target on Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Stifel Nicolaus lowered their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Monday. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and an average target price of $26.46.

Avantor Trading Down 2.1 %

Avantor stock traded down $0.40 during trading hours on Monday, hitting $18.77. The company had a trading volume of 2,704,222 shares, compared to its average volume of 5,111,776. Avantor has a 1 year low of $18.49 and a 1 year high of $28.00. The firm has a market cap of $12.77 billion, a P/E ratio of 41.14, a P/E/G ratio of 3.87 and a beta of 1.28. The company has a 50-day moving average price of $21.73 and a two-hundred day moving average price of $23.47. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter in the previous year, the company posted $0.22 earnings per share. On average, sell-side analysts anticipate that Avantor will post 0.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in shares of Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after purchasing an additional 1,285 shares during the last quarter. UMB Bank n.a. acquired a new position in shares of Avantor during the third quarter worth about $49,000. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after buying an additional 3,700 shares during the last quarter. Oliver Luxxe Assets LLC increased its stake in Avantor by 36.7% in the third quarter. Oliver Luxxe Assets LLC now owns 84,009 shares of the company’s stock valued at $2,173,000 after purchasing an additional 22,534 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Avantor during the 3rd quarter worth $139,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.